Claims for Patent: 12,433,859

Summary for Patent: 12,433,859

Title:	Oral solutions comprising lisdexamfetamine salts
Abstract:	Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.
Inventor(s):	Georgios LIOLIOS, Ioannis Psarrakis
Assignee:	Adalvo Ltd
Application Number:	US18/792,999
Patent Claims:	1. An oral pharmaceutical solution comprising 10 mg/ml of lisdexamfetamine dimesylate and a pharmaceutically acceptable aqueous carrier comprising a buffer and a non-aqueous cosolvent selected from a glycol, a polyol and a mixture thereof, wherein the pH of the solution is from 6.0 to 9.0, and wherein the solution contains less than 1.0% total impurities after four weeks. 2. The oral pharmaceutical solution according to claim 1, wherein the solution is free of any antioxidant. 3. The oral pharmaceutical solution according to claim 1, wherein the solution is free of an antioxidant selected from the group consisting of sodium metabisulfite, butylated hydroxy anisole, butylated hydroxytoluene, ethylenediamine tetraacetic acid, ascorbic acid, α-tocopherol, and propyl gallate. 4. The oral pharmaceutical solution according to claim 1, wherein the total concentration of the non-aqueous cosolvent is from 5 mg/ml to 300 mg/ml. 5. The oral pharmaceutical solution according to claim 1, wherein the total concentration of the non-aqueous cosolvent is from 50 mg/ml to 250 mg/ml. 6. The oral pharmaceutical solution according to claim 1, wherein the total concentration of the non-aqueous cosolvent is from 100 mg/ml to 200 mg/ml. 7. The oral pharmaceutical solution according to claim 1, wherein the pH of the solution is from 6.0 to 8.5. 8. The oral pharmaceutical solution according to claim 1, wherein the pH of the solution is from 6.5 to 8.0. 9. The oral pharmaceutical solution of claim 1, wherein the oral solution comprises a second non-aqueous cosolvent. 10. The oral pharmaceutical solution of claim 1, wherein the oral solution comprises an antimicrobial preservative. 11. The oral pharmaceutical solution of claim 1, wherein the non-aqueous cosolvent is selected from maltitol, glycerol, mannitol, sorbitol, xylitol, propylene glycol, low molecular weight polyethylene glycol, and a mixture thereof. 12. The oral pharmaceutical solution of claim 1, wherein the buffer is selected from ascorbic acid, acetic acid, tartaric acid, citric acid monohydrate, sodium citrate, potassium citrate, acetic acid, sodium acetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate, and a mixture thereof. 13. The oral pharmaceutical solution according to claim 7, wherein the total concentration of the non-aqueous cosolvent is from 5 mg/ml to 300 mg/ml. 14. The oral pharmaceutical solution according to claim 7, wherein the total concentration of the non-aqueous cosolvent is from 50 mg/ml to 250 mg/ml. 15. The oral pharmaceutical solution according to claim 7, wherein the total concentration of the non-aqueous cosolvent is from 100 mg/ml to 200 mg/ml. 16. The oral pharmaceutical solution of claim 7, wherein the oral solution comprises an antimicrobial preservative. 17. The oral pharmaceutical solution of claim 7, wherein the non-aqueous cosolvent is selected from maltitol, glycerol, mannitol, sorbitol, xylitol, propylene glycol, low molecular weight polyethylene glycol and a mixture thereof. 18. The oral pharmaceutical solution of claim 7, wherein the buffer is selected from ascorbic acid, acetic acid, tartaric acid, citric acid monohydrate, sodium citrate, potassium citrate, acetic acid, sodium acetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate, and a mixture thereof. 19. A method of treating Attention Deficit Hyperactivity Disorder in a subject in need thereof, the method comprising administering to the subject the oral pharmaceutical solution of claim 1. 20. The method of claim 19, wherein the subject is a child. 21. The oral pharmaceutical solution of claim 1, wherein the solution contains less than 1.0% total impurities after four weeks at 40° C. and 75% relative humidity. 22. The method of claim 19, wherein the solution contains less than 1.0% total impurities after four weeks of storage at 40° C. and 75% relative humidity.